Editorial, J Biocatal Biotransformation Vol: 1 Issue: 2
Thioredoxin Catalysis and Inflammasome Regulation: Directions for Future Research
| Prasanna Tamarapu Parthasarathy, Phillips Oluwakemi and Narasaiah Kolliputi* | |
| Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., Tampa, FL 33612, USA | |
| Corresponding author : Narasaiah Kolliputi Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 19, Tampa, FL 33612, USA Tel: 813-974-5419; Fax: 813-974-8575 E-mail: nkollipu@health.usf.edu |
|
| Received: September 20, 2012 Accepted: September 24, 2012 Published: September 28, 2012 | |
| Citation: Kolliputi N, Parthasarathy PT, Oluwakemi P (2012) Thioredoxin Catalysis and Inflammasome Regulation: Directions for Future Research. J Biocatal Biotransformation 1:2. doi:10.4172/2324-9099.1000e107 |
Abstract
Thioredoxin Catalysis and Inflammasome Regulation: Directions for Future Research
The Thioredoxin (Trx) system, ubiquitous from Archaea to man, participates in several metabolic processes, e.g. intracellular signaling of reactive oxygen species (ROS), transcription, DNA synthesis. Alterations in this system have been shown to induce ROS-related cardiovascular disorders, myocarditis and ischemia. Recent findings indicate that the Trx system mediates redoxinduced cell death, in response to anticancer agents to a large extent. Thioredoxin is a member of the Trx system, that also includes Trx reductase (TrxR) and NADPH.